BioScreening - organic compounds for screening

30.01.2004 Junuary 2004 News Archive
Argenta Discovery and TTP LabTech have announced a collaborative agreement to expand Argenta's biology and eADMET capabilities through the incorporation of TTP LabTech's Acumen Explorer(TM) screening platform. Argenta and TTP LabTech will also work together to develop novel screening assays within the drug discovery process. PR-TT Labtech 1/29/04

Tripos has announced an amendment to its strategic collaboration with Pfizer for the design, synthesis and purification of druglike compounds. Tripos will reduce file enrichment activities with Pfizer, but partially offsetting this reduction, Tripos will engage in new work for Pfizer in the areas of hit follow-up and large library production, the next steps in the drug discovery process that follow directly from screening library compounds. PR-Tripos 1/29/04

Avidex and ChemOvation announced that they have signed an agreement to extend their 2003 small molecule programme for Rhudex(R), Avidex's CD80 inhibitor for rheumatoid arthritis. Under the terms of the agreement, full details of which have not been disclosed, ChemOvation will be providing Avidex with medicinal chemistry services and expertise for selection of a follow-on Lead Candidate in this important therapeutic approach. PR-Avidex 1/28/04

Argenta Discovery Ltd has entered into a contract research agreement with GlaxoSmithKline (GSK). Argenta will provide discovery research capabilities to GSK's Respiratory and Inflammatory Diseases Centre of Excellence for Drug Discovery based in Stevenage, UK, and to its Psychiatry Diseases CEDD, based in Verona, Italy. The new agreement follows a successful collaboration undertaken during the previous 12 months. PR-Argenta 1/26/04

Iconix Pharmaceuticals, Inc. has entered into a research and license agreement with Bristol-Myers Squibb Company. Under this agreement, Bristol-Myers Squibb will access Iconix's DrugMatrix(TM) chemogenomics system and its library of Drug Signatures(TM). DrugMatrix is a reference source of information on the genomic effects of drug and chemical treatments. PR-Iconix 1/21/04

Symyx Technologies has entered into a new agreement with Merk for the development and delivery of a Symyx Discovery Tools(R) workflow. This workflow will extend Symyx's high-throughput technologies into the area of biocatalysis, with the development of a workflow that enables scientists to perform and analyze up to 400 automated enzyme reactions a day. This high-throughput capability is expected to enable Merck scientists to reduce by a factor of five to ten the time, material, and resources required to screen enzymes and reaction conditions for a particular synthesis. PR-Symyx 1/15/04

Archemix has announced a funded target validation collaboration with Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica N.V. The collaboration will focus on validating G protein-coupled receptor (GPCR) targets. PR-Archemix 1/14/04

Metabasis Therapeutics and Merck announced a collaboration to research, develop and commercialize novel small molecule therapeutics for the treatment of hepatitis C virus infections. Under the terms of the agreement, Merck will contribute drug candidates to the collaboration and Metabasis will apply its liver targeting, HepDirect™ prodrug technology to identify novel drugs for treatment of this disease. PR-Metabasis 1/14/04

Archemix Corp., has announced a funded target validation collaboration with Johnson & Johnson Pharmaceutical R & D, Division of Janssen Pharmaceutica N.V. The collaboration will focus on validating G protein-coupled receptor (GPCR) targets. PR-Archemix 1/13/04

Pharmacopeia has reached a research milestone in its collaboration with AstraZeneca. In the collaboration, Pharmacopeia identified lead compounds from their compound collection that were active against a gastrointestinal receptor target critical to AZ's research programs. The milestone was triggered by AZ's acceptance of the compounds identified from the collaboration. PR-Pharmacopeia 1/13/04

ActivX Biosciences, Inc. and Kyorin Pharmaceutical Co. Ltd., have entered into a new collaboration to develop protein activity profiles for certain Kyorin compounds. Under the agreement, ActivX agreed to utilize its technology to analyze specific protein activities to provide greater understanding of the biological activity of Kyorin's compounds that have potential for the treatment of metabolic diseases. PR-Activx 1/13/04
More bioscreening news...

new | june 2010 | october 2009 | may 2009 | january 2009 | october 2008 | april 2008 | january 2008 | october 2007 | september 2007 | august 2007 | march 2007 | february 2007 | january 2007 | december 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004 | october 2004 | september 2004 | august 2004 | july 2004 | june 2004 | may 2004 | april 2004 | march 2004 | february 2004 | january 2004 | december 2004 | november 2003 | october 2003 | september 2003 | august 2003 | july 2003 | june 2003 | may 2003